(Press-News.org) JACKSONVILLE, Fla. — An international team of researchers led by neuroscientists at Mayo Clinic in Florida has found a genetic variation they say protects against Parkinson's disease. The gene variants cut the risk of developing the disease by nearly 20 percent in many populations. The study, published in the online Aug. 31 issue of Lancet Neurology, also reports the discovery of different variants of the same gene, LRRK2— the most important Parkinson's risk gene found to date — that double Parkinson's risk in Caucasians and Asians.
Parkinson's disease is a common movement disorder that affects 1 to 2 percent of people over age 65. The researchers say that although the relative influence of the variants in this study on risk is small, given the late-onset nature of Parkinson's, any variation that can delay the disease is important. In addition, the finding provides evidence that Parkinson's disease is influenced by multiple genetic risks that act together to cause disease.
"The idea that Parkinson's disease occurs mostly in a random sporadic fashion is changing," says lead investigator Owen Ross, Ph.D., a neuroscientist at Mayo Clinic Florida. "Our study, one of the largest to date in the study of the genetics of Parkinson's disease, shows that a single gene, LRRK2, harbors both rare and common variants that in turn alter the susceptibility to PD in diverse populations.''
Researchers hope to use these and future genetic findings to predict who is at risk of Parkinson's and to develop novel targeted therapies, Dr. Ross says.
The Genetic Epidemiology of Parkinson's Disease consortium that contributed to the three-year study included investigators from 23 sites representing 15 countries on five continents. The investigators contributed clinical samples on a total of 15,540 individuals (8,611 PD patients and 6,929 controls). The researchers in Mayo Clinic Florida, funded by The Michael J. Fox Foundation for Parkinson's Research and the Mayo Clinic Morris K. Udall Center of Excellence in Parkinson's disease Research, then quantified Parkinson's risk for each LRRK2 variant. Co- investigator Matthew Farrer, Ph.D., is a former Mayo Clinic neuroscientist now at the University of British Columbia in Vancouver.
"This is an important study that will help us learn more about how the same gene can both increase and reduce risk of late-onset, sporadic Parkinson's disease, the kind that affects most people," says co-author Zbigniew Wszolek, M.D., a Mayo Clinic neurologist who has helped build international collaborations at Mayo Clinic. "Our goal is to find out how we can intervene in this process to help prevent development of this disease."
In 2004, Mayo researchers led by Dr. Wszolek discovered that the little understood LRRK2 gene was responsible for causing a form of "familial" or inherited Parkinson's. "Through this study and subsequent follow-up investigation, we and others identified a LRRK2 variant (G2019S) which turned out to be the most common genetic cause of familial PD yet found. For example, it is found in more than 30 percent of Arab-Berber patients with the disease," he says. To date, seven such familial pathogenic LRRK2 variants have been discovered in different ethnic populations.
However, LRRK2 variation has also been found to increase the risk of sporadic late-onset Parkinson's, so in this study, researchers set out to address every possible variant in the part of the LRRK2 gene that codes for protein production to determine which variants affect risk, and by how much. The researchers found that common and rare variants contributed to late-onset sporadic PD in both a risk or protective manner. Dr Ross adds that there remain many more PD risk genes to be found outside of LRRK2, and that together they contribute to a significantly higher likelihood of developing PD.
Major funding for the study also came from the National Institutes of Health, Mayo Foundation, and several international funding agencies.
###
About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit www.mayoclinic.org/about/ and www.mayoclinic.org/news2010-jax/5837.html.
END
Berkeley – Exposure during pregnancy to flame retardant chemicals commonly found in the home is linked to lower birthweight babies, according to a new study led by researchers at the University of California, Berkeley's School of Public Health.
In the study, to appear Tuesday, Aug. 30, in the peer-reviewed publication American Journal of Epidemiology, researchers found that every tenfold increase in levels of PBDEs, or polybrominated diphenyl ethers, in a mother's blood during pregnancy corresponded to a 115 gram (4.1 ounce) drop in her baby's birthweight.
"This is ...
Writing in the journal Nature Communications, a collaboration between the Universities of Manchester and Cambridge, which includes Nobel Prize winning scientists Professor Andre Geim and Professor Kostya Novoselov, has discovered a crucial recipe for improving characteristics of graphene devices for use as photodetectors in future high-speed optical communications.
By combining graphene with metallic nanostructures, they show a twentyfold enhancement in harvesting light by graphene, which paves the way for advances in high-speed internet and other communications.
By ...
The US economy continues to produce conflicting headlines and consumer anxiety on a daily basis as unemployment remains above 9 percent. Those looking for a short-term financial solution routinely turn to online lending resources such as Personal Cash Advance, which promotes best loan options such as secure cash advances, payday loans, and other personal loans.
"Our new guide to finding the best loans has been met with much enthusiasm from consumers as the economy continues to heal," PersonalCashAdvance.com company spokesperson Neil Cutting said. "As a ...
"Our data indicate that the brain becomes hypersensitive to rewards when this co-signaling of glutamate and dopamine does not function. Lower doses than normal are enough to increase the propensity to ingest the substance, and this is true of both sugar and cocaine," says Åsa Mackenzie, associate professor of neuroscience at Uppsala University and the researcher who led the study.
Addiction disorders are a major social problem, and we lack sufficient knowledge of how they arise and how various substances impact the brain. The brain's reward system gives us feelings of ...
Since 2007 Transcatheter Aortic Valve Implantation (TAVI) has become an alternative treatment for elderly patients with severe aortic stenosis at high risk for surgical aortic valve replacement. At present, durability and hemodynamic performance of transcatheter aortic valves remain unclear. Our single center data of the German Heart Center in Munich demonstrates a sustained improvement of hemodynamic performance up to 3 years after CoreValve implantation.
Aortic valve stenosis (AS) is the most frequent heart valve disease in Europe and North America. The most common ...
Primary PCI is the best reperfusion therapy for patients presenting with acute ST-elevation myocardial infarction. CJ Terkelsen and co-workers used the Western Denmark Heart Registry to describe the implementation of primary PCI in Denmark. Their study (including almost 10,000 patients) showed that a strategy with early diagnosis based on ECG recording in the ambulance and directing the patients straight to the catherization laboratory in the Primary PCI Centre, was associated with a lower mortality.
Direct access to PPCI is unfortunately still not possible in many European ...
Results from the SCAAR study, presented at the ESC Congress 2011 today, showed that Percutaneous Coronary Intervention (PCI) with "new generation" Drug Eluting Stents, was associated with a 38% lower risk of clinically meaningful restenosis and a 50% lower risk of stent thrombosis compared to old generation DES.
Although many trials and studies support the overall early and mid-term safety and efficacy of first-generation drug-eluting stents, there has been concern on their long-term safety, especially regarding the potential risk of late stent thrombosis as well as ...
With a great response from the audience Christopher Flach's film Madeleine Castaing, ended the last days of the Cesis Festival along with the final concert "Imants Kalnins and Philip Glass." Attended by more than 1800 visitors, this years 2011Festival contained a rich program featuring a diverse range of art forms included classical music concerts, visual art exhibitions, films and drama performances.
Christopher Flach's film "Madeleine Castaing," is the documentary that explores the personality and influence of the French decorator and antique dealer. ...
Acute myocardial Infarction (AMI) is a major cause of death and disability. Worldwide, one in eight patients die of an ischemic heart disease. Its rapid and accurate diagnosis is critical for the initiation of effective evidence based medical management, including early revascularization, but is still an unmet clinical need. The gradual implementation of high-sensitive cardiac troponins (hs-cTnT) in clinical practice has helped clinicians to detect and treat patients with acute myocardial infarction earlier than with conventional assays. But, high-sensitive assays have ...
Compared to patients who had persistently high platelet reactivity, those who achieved low platelet reactivity, according to the VerifyNow P2Y12 Test, had a reduced incidence of cardiovascular death, heart attack and stent thrombosis, as indicated by a clinical trial presented today at the ESC Congress 2011.
These findings were part of a secondary analysis of the Gauging Responsiveness with A VerifyNow P2Y12 Assay- Impact on Thrombosis and Safety (GRAVITAS) trial, the largest prospective trial to date to test the clinical efficacy of antiplatelet therapy modification, ...
